my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
25-05-2012: Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. Financial terms were not disclosed.
“We are pleased to expand our leading IP estate with a license to the Baulcombe patent,” said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. “Alnylam continues to leverage its patent estate for the advancement of innovative medicines to patients and to enable the entire RNAi therapeutics field, with over 30 license agreements formed to date.”
U.S. Patent No. 8,097,710 issued in January 2012, and is the most recently issued patent in PBL’s IP estate in short RNAs derived from the seminal work of Prof David Baulcombe and Dr Andrew Hamilton, at The Sainsbury Laboratory (Norwich, UK).
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. Financ ... more
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis
Alnylam Pharmaceuticals, Inc. announced that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and commercia ... more
IMM, Cenix and Alnylam Discover New Targets in Malaria Infection with RNAi Technology
Alnylam Pharmaceuticals, Inc. and Cenix BioScience GmbH announced the publication of a new study in the journal PLoS Pathogens demonstrating in vitro and in vivo RNAi-mediated silencing of novel host factors involved in malaria infection. The work resulted from an ongoing malaria research ... more
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the cur ... more
PBL awarded two US patents on RNAi
Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of ind ... more
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. Financ ... more
Plant Bioscience Limited awarded US patent on RNAi
Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a w ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
